Zum Inhalt springen

Einmalige Infusion von CAR-T-Zellen ersetzt immunhemmende Medikamente

Diese Erkenntnisse sind ein Durchbruch in der Immunmedizin. Es ist bereits schon jetzt möglich, die CAR-T-Zelltherapie im Rahmen der sogenannten CASTLE-Studie, die am Uniklinikum Erlangen durchgeführt wird, bei weiteren Patientinnen und Patienten mit schweren Formen des systemischen Lupus erythematodes, der systemischen Sklerose und der Myositis anzuwenden.

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — The post CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results appeared first on Bio Tech Winners. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare The post Diagnostics Industry Leader… Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. („Dyadic“ or the „Company“) (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute… Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – The post Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv appeared first on Bio Tech Winners. Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv